Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

TFX vs DBVT vs ALKS vs ICU

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TFX
Teleflex Incorporated

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$5.83B
5Y Perf.-34.6%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+12.9%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+58.5%
ICU
SeaStar Medical Holding Corporation

Biotechnology

HealthcareNASDAQ • US
Market Cap$29M
5Y Perf.-98.1%

TFX vs DBVT vs ALKS vs ICU — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TFX logoTFX
DBVT logoDBVT
ALKS logoALKS
ICU logoICU
IndustryMedical - Instruments & SuppliesBiotechnologyBiotechnologyBiotechnology
Market Cap$5.83B$1712.35T$5.90B$29M
Revenue (TTM)$2.81B$0.00$1.56B$881K
Net Income (TTM)$-1.01B$-168M$153M$-14M
Gross Margin53.3%65.4%95.3%
Operating Margin5.6%12.3%-15.8%
Forward P/E19.6x24.8x
Total Debt$2.73B$22M$70M$574K
Cash & Equiv.$393M$194M$1.12B$2M

TFX vs DBVT vs ALKS vs ICULong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TFX
DBVT
ALKS
ICU
StockSep 22May 26Return
Teleflex Incorporat… (TFX)10065.4-34.6%
DBV Technologies S.… (DBVT)100112.9+12.9%
Alkermes plc (ALKS)100158.5+58.5%
SeaStar Medical Hol… (ICU)1001.9-98.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: TFX vs DBVT vs ALKS vs ICU

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ICU leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Teleflex Incorporated is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. ALKS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
TFX
Teleflex Incorporated
The Income Pick

TFX is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 0 yrs, beta 1.06, yield 1.0%
  • -10.3% 10Y total return vs ALKS's -11.0%
  • Better valuation composite
  • 1.0% yield; the other 3 pay no meaningful dividend
Best for: income & stability and long-term compounding
DBVT
DBV Technologies S.A.
The Secondary Option

DBVT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ALKS
Alkermes plc
The Growth Play

ALKS is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • 9.8% margin vs ICU's -15.5%
Best for: growth exposure and sleep-well-at-night
ICU
SeaStar Medical Holding Corporation
The Growth Leader

ICU carries the broadest edge in this set and is the clearest fit for growth and stability.

  • 12.0% revenue growth vs DBVT's -100.0%
  • Beta 1.06 vs DBVT's 1.26
  • +291.9% vs TFX's +9.0%
Best for: growth and stability
See the full category breakdown
CategoryWinnerWhy
GrowthICU logoICU12.0% revenue growth vs DBVT's -100.0%
ValueTFX logoTFXBetter valuation composite
Quality / MarginsALKS logoALKS9.8% margin vs ICU's -15.5%
Stability / SafetyICU logoICUBeta 1.06 vs DBVT's 1.26
DividendsTFX logoTFX1.0% yield; the other 3 pay no meaningful dividend
Momentum (1Y)ICU logoICU+291.9% vs TFX's +9.0%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

TFX vs DBVT vs ALKS vs ICU — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TFXTeleflex Incorporated
FY 2025
Vascular Access
46.1%$918M
Interventional
32.5%$648M
Surgical
21.0%$418M
Other
0.5%$9M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
ICUSeaStar Medical Holding Corporation

Segment breakdown not available.

TFX vs DBVT vs ALKS vs ICU — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGICU

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 3 of 6 comparable metrics.

TFX and DBVT operate at a comparable scale, with $2.8B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ICU's -15.5%. On growth, ICU holds the edge at +169.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTFX logoTFXTeleflex Incorpor…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcICU logoICUSeaStar Medical H…
RevenueTrailing 12 months$2.8B$0$1.6B$881,000
EBITDAEarnings before interest/tax$280M-$112M$212M-$14M
Net IncomeAfter-tax profit-$1.0B-$168M$153M-$14M
Free Cash FlowCash after capex$249M-$151M$392M-$14M
Gross MarginGross profit ÷ Revenue+53.3%+65.4%+95.3%
Operating MarginEBIT ÷ Revenue+5.6%+12.3%-15.8%
Net MarginNet income ÷ Revenue-35.9%+9.8%-15.5%
FCF MarginFCF ÷ Revenue+8.9%+25.1%-16.1%
Rev. Growth (YoY)Latest quarter vs prior year-21.8%+28.2%+169.1%
EPS Growth (YoY)Latest quarter vs prior year-108.7%+91.5%-4.1%+88.2%
ALKS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — TFX and ALKS each lead in 2 of 5 comparable metrics.

On an enterprise value basis, ALKS's 17.3x EV/EBITDA is more attractive than TFX's 18.8x.

MetricTFX logoTFXTeleflex Incorpor…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcICU logoICUSeaStar Medical H…
Market CapShares × price$5.8B$1712.35T$5.9B$29M
Enterprise ValueMkt cap + debt − cash$8.2B$1712.35T$4.9B$28M
Trailing P/EPrice ÷ TTM EPS-6.50x-0.76x24.76x-0.73x
Forward P/EPrice ÷ next-FY EPS est.19.59x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple18.82x17.25x
Price / SalesMarket cap ÷ Revenue2.93x4.00x215.18x
Price / BookPrice ÷ Book value/share1.88x0.66x3.28x
Price / FCFMarket cap ÷ FCF23.75x12.28x
Evenly matched — TFX and ALKS each lead in 2 of 5 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to TFX's 0.87x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricTFX logoTFXTeleflex Incorpor…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcICU logoICUSeaStar Medical H…
ROE (TTM)Return on equity-28.3%-130.2%+8.8%-119.2%
ROA (TTM)Return on assets-13.9%-89.0%+5.4%-88.0%
ROICReturn on invested capital+3.4%+18.9%
ROCEReturn on capital employed+4.0%-145.7%+14.2%
Piotroski ScoreFundamental quality 0–95476
Debt / EquityFinancial leverage0.87x0.13x0.04x
Net DebtTotal debt minus cash$2.3B-$172M-$1.0B-$1M
Cash & Equiv.Liquid assets$393M$194M$1.1B$2M
Total DebtShort + long-term debt$2.7B$22M$70M$574,000
Interest CoverageEBIT ÷ Interest expense-2.02x-189.82x32.30x-209.88x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — DBVT and ICU each lead in 2 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $189 for ICU. Over the past 12 months, ICU leads with a +291.9% total return vs TFX's +9.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ICU's -53.7% — a key indicator of consistent wealth creation.

MetricTFX logoTFXTeleflex Incorpor…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcICU logoICUSeaStar Medical H…
YTD ReturnYear-to-date+7.9%+4.9%+25.3%+84.7%
1-Year ReturnPast 12 months+9.0%+110.4%+16.5%+291.9%
3-Year ReturnCumulative with dividends-47.6%+19.7%+14.5%-90.1%
5-Year ReturnCumulative with dividends-66.4%-69.1%+60.9%-98.1%
10-Year ReturnCumulative with dividends-10.3%-87.0%-11.0%-98.1%
CAGR (3Y)Annualised 3-year return-19.4%+6.2%+4.6%-53.7%
Evenly matched — DBVT and ICU each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and ICU each lead in 1 of 2 comparable metrics.

ICU is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTFX logoTFXTeleflex Incorpor…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcICU logoICUSeaStar Medical H…
Beta (5Y)Sensitivity to S&P 5001.06x1.26x1.06x1.06x
52-Week HighHighest price in past year$139.63$26.18$36.60$5.08
52-Week LowLowest price in past year$100.18$7.53$25.17$0.22
% of 52W HighCurrent price vs 52-week peak+94.3%+76.3%+96.7%+95.6%
RSI (14)Momentum oscillator 0–10048.548.160.265.7
Avg Volume (50D)Average daily shares traded884K252K2.3M150K
Evenly matched — ALKS and ICU each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TFX as "Buy", DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 0.4% for TFX (target: $132). TFX is the only dividend payer here at 1.02% yield — a key consideration for income-focused portfolios.

MetricTFX logoTFXTeleflex Incorpor…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcICU logoICUSeaStar Medical H…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$132.20$46.33$44.00
# AnalystsCovering analysts291528
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises000
Dividend / ShareAnnual DPS$1.35
Buyback YieldShare repurchases ÷ mkt cap+5.1%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

TFX vs DBVT vs ALKS vs ICU: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is TFX or DBVT or ALKS or ICU a better buy right now?

For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.

2% revenue growth year-over-year, versus -34. 6% for Teleflex Incorporated (TFX). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Teleflex Incorporated (TFX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TFX or DBVT or ALKS or ICU?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: TFX returned -10. 3% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TFX or DBVT or ALKS or ICU?

By beta (market sensitivity over 5 years), SeaStar Medical Holding Corporation (ICU) is the lower-risk stock at 1.

06β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 19% more volatile than ICU relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 87% for Teleflex Incorporated — giving it more financial flexibility in a downturn.

04

Which is growing faster — TFX or DBVT or ALKS or ICU?

By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.

2% versus -34. 6% for Teleflex Incorporated (TFX). On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78. 1% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TFX or DBVT or ALKS or ICU?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is TFX or DBVT or ALKS or ICU more undervalued right now?

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

07

Which pays a better dividend — TFX or DBVT or ALKS or ICU?

In this comparison, TFX (1.

0% yield) pays a dividend. DBVT, ALKS, ICU do not pay a meaningful dividend and should not be held primarily for income.

08

Is TFX or DBVT or ALKS or ICU better for a retirement portfolio?

For long-horizon retirement investors, Teleflex Incorporated (TFX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06), 1. 0% yield). Both have compounded well over 10 years (TFX: -10. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between TFX and DBVT and ALKS and ICU?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TFX pays a dividend while DBVT, ALKS, ICU do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TFX

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 31%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

ICU

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 84%
  • Gross Margin > 57%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.